Next Article in Journal
Altering the Course of Technologies to Monitor Loosening States of Endoprosthetic Implants
Next Article in Special Issue
Graphene-Oxide-Based Electrochemical Sensors for the Sensitive Detection of Pharmaceutical Drug Naproxen
Previous Article in Journal
Underwater Target Tracking Using Forward-Looking Sonar for Autonomous Underwater Vehicles
Previous Article in Special Issue
Monitoring of Chemical Risk Factors for Sudden Infant Death Syndrome (SIDS) by Hydroxyapatite-Graphene-MWCNT Composite-Based Sensors
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Sensors
Volume 20
Issue 1
10.3390/s20010103
sensors-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Metabolic Syndrome—An Emerging Constellation of Risk Factors: Electrochemical Detection Strategies

by
Madhurantakam Sasya
1,2,3,
K. S. Shalini Devi
2,3,
Jayanth K. Babu
2,4,
John Bosco Balaguru Rayappan
2,4 and
Uma Maheswari Krishnan
1,3,5,*
1
Department of Molecular Physiology, School of Medicine, Niigata University, Niigata-9518510, Japan
2
Centre for Nanotechnology & Advanced Biomaterials (CeNTAB), SASTRA Deemed-to-be University, Thanjavur 613401, India
3
School of Chemical & Biotechnology, SASTRA Deemed-to-be University, Thanjavur 613401, India
4
School of Electrical & Electronics Engineering, SASTRA Deemed-to-be University, Thanjavur 613401, India
5
School of Arts, Science & Humanities, SASTRA Deemed-to-be University, Thanjavur 613401, India
*
Author to whom correspondence should be addressed.
Sensors 2020, 20(1), 103; https://doi.org/10.3390/s20010103
Submission received: 15 October 2019 / Revised: 15 November 2019 / Accepted: 11 December 2019 / Published: 23 December 2019
(This article belongs to the Special Issue Sensors for Human Safety Monitoring)
Browse Figures
Review Reports Versions Notes

Abstract

:
Metabolic syndrome is a condition that results from dysfunction of different metabolic pathways leading to increased risk of disorders such as hyperglycemia, atherosclerosis, cardiovascular diseases, cancer, neurodegenerative disorders etc. As this condition cannot be diagnosed based on a single marker, multiple markers need to be detected and quantified to assess the risk facing an individual of metabolic syndrome. In this context, chemical- and bio-sensors capable of detecting multiple analytes may provide an appropriate diagnostic strategy. Research in this field has resulted in the evolution of sensors from the first generation to a fourth generation of ‘smart’ sensors. A shift in the sensing paradigm involving the sensing element and transduction strategy has also resulted in remarkable advancements in biomedical diagnostics particularly in terms of higher sensitivity and selectivity towards analyte molecule and rapid response time. This review encapsulates the significant advancements reported so far in the field of sensors developed for biomarkers of metabolic syndrome.

Graphical Abstract

1. Introduction

Advances in the health sector have greatly improved the health and life span of people. However, modern technological advancements have also resulted in dramatic changes in the way of life of individuals from both the calorie intake and energy consumption perspectives. A gross imbalance between the calories consumed and energy spent has resulted in the emergence of a new set of metabolic and age-related disorders that makes an individual more susceptible to chronic diseases, which if not detected in the early stages can turn fatal [1]. Metabolic syndrome (MetS) is a condition that refers to a cluster of risk factors that arises due to several dysfunctional biochemical pathways, thereby predisposing an individual to various non-communicable diseases [2]. MetS has emerged as a major health concern worldwide in the recent decades and is possibly connected with the life-style changes in the modern era [3]. Several risk factors have been identified to be part of the constellation of abnormalities leading to MetS (Figure 1). These include elevated blood glucose, triglycerides, cholesterol levels, obesity, oxidative stress and blood pressure [4,5,6,7,8].
Although each of the abnormalities cited reduces the quality of life when present independently, in combination they lead to severe health problems with increased risk of mortality. An individual is diagnosed with metabolic syndrome when at least three or more abnormalities that interfere with the body’s normal functioning are present [8].

2. Diagnosis of Metabolic Syndrome (MetS)

MetS is a complex, multi-factorial condition that pre-disposes an individual to several severe complications like cancer, cardiovascular diseases, chronic kidney diseases and neurodegenerative disorders [9]. Diagnosis of MetS is complicated as there are many risk factors that are associated with MetS. The identification of new inter-relationships between the factors has led to inclusion of new risk parameters for MetS. However, contradictory results from some studies have led to the elimination of several factors from the risk list. As a result, the definition of MetS has constantly evolved over the years. A scan of literature reveals that the first description of inter-relations between diabetes and hypertension was made during 1915–1916 by the physicians Hitzenberger and Rittner-Quittner [5,10]. Later, Kylin described the common mechanisms involved in the development of hyperglycemia, hypertension and hyperuricemia suggesting that these conditions arise due to common risk factors. During the late 1940s and early 1950s, several researchers identified obesity as the chief cause leading to the development of diabetes, hypertension, atherosclerosis, gout and dyslipidemia [5]. The nomenclature for this cluster of diseases caused due to inter-dependent dysfunctional metabolic pathways has evolved over the years and by common consensus is referred to as metabolic syndrome in the modern era (Table 1).
A large number of studies carried out on populations of different ethnicities, races, genders, ages and life-style habits have led to the evolution of the criteria to define MetS. MetS is a constellation of disorders and thus far only independent conditions have been detected using sensors. Individual quantification of glucose, triglycerides and superoxide has proved inadequate for accurate diagnosis of MetS. Combination of conditions that predispose an individual to MetS and the criteria for diagnosis of MetS has constantly been modified since the later 1990s. These are tabulated in Table 2. Attempts to develop multi-analyte panels using electrochemical methods are under active research currently and it may soon represent the next generation of smart diagnostic strategy for MetS in the future.
The guidelines for diagnosis of MetS as prescribed by IDF has been challenged by several research groups with respect to the cut-off values for the parameters as well as with respect to the parameters itself. The American Diabetes Association (ADA) in 2009 had challenged the inclusion of waist circumference as a criteria of MetS because large variations have been reported between individuals across different ethnicities and body stature [6]. Currently, the revised guidelines proposed by National Cholesterol Education Program—Adult Treatment Panel-III NCEP-ATP-III is being followed world-wide for diagnosis of MetS. But there are several caveats in this method also. Definition of obesity with respect to waist circumference measurements has not been universally accepted as there are many deviations reported [11]. Exclusion of several other quantifiable factors has been questioned by many groups. In 2010, the World Health Organization (WHO) had claimed that MetS is more of an educational concept rather than of clinical value. But, the recent consensus that has emerged is that MetS is a pre-disease condition that has emerged as a new age malady which makes an individual prone to many non-communicable diseases and reduces the survival rate [12]. The search for the most suitable predictors of MetS is still on earnestly across the globe.
The treatment modalities for MetS need to be tailored to cure the abnormalities presented by the individual. In other words, if two individuals are diagnosed with diabetes, the treatment regimen will differ based on the existence of other abnormalities in each individual. This necessitates accurate diagnostic tools for measurement of the risk factors. The following section details the advancements in the diagnostic field for major parameters of MetS.

3. Sensors for Metabolic Syndrome

As MetS is characterized by many risk factors that may vary from one individual to another, conventional methods have employed qualitative and quantitative methods to detect each risk factor independently. Distinct biomarkers found in body fluids or tissues that indicate an abnormal condition have to be chosen to identify each risk factor specifically. Conventional methods of diagnosing risk factors for metabolic syndrome involve measurement of individual parameters such as glucose, triglycerides, HDL and blood pressure (hypertension) apart from measurement of the waist circumference and body mass index (BMI) of the individual [13]. If at least three parameters are found to be abnormal, the person is diagnosed with MetS. But this entire process takes a long time; moreover, quick analysis is not possible using conventional strategies.
Most of the advances in detection of MetS complications have happened in the diagnosis of diabetes. Conventional methods for diagnosis of diabetes involve measurement of glycated hemoglobin levels and glucose levels at various time intervals during the day employing enzymatic and colorimetric assays. Hand-held glucometers based on enzymatic detection of glucose are also available commercially [14]. However, the enzyme-based strips cannot be reused and hence the method becomes expensive. Efforts to identify new methods to expand the detection range, reduce the response time and reuse the sensing element are underway in different parts of the globe. The strategies for the diagnosis of cardiovascular diseases include measurement of lipid profile comprising cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL), and triglycerides to identify dyslipidemia conditions. These analyses are carried out using biochemical assays that require higher sample volume and longer analysis time. In addition, plaque deposits arising due to atherosclerosis or vascular abnormalities are diagnosed employing imaging techniques such as X-rays, echocardiograms, electro-cardiograms (ECG), computed tomography (CT) scans, magnetic resonance imaging (MRI), laser dopplers and angiography. All these methods are highly expensive, time-consuming, require large and sophisticated instrumentation that are not portable and also need trained personnel for recording and analysis [15].
Renal failure has been conventionally diagnosed using biochemical assays for analyzing blood serum for creatinine levels and urea nitrogen [16]. Urine output and a total urine analysis (urinalysis) comprising a combination of biochemical assays to quantify urine protein and albumin, microscopic and visual examination to qualitatively detect abnormalities in colour and transparency as well as microbiological examination is carried out to detect renal dysfunction. Glomerular filtration rate and creatinine clearance rates are measured using radioisotopes or cystatin C [17]. Imaging techniques such as ultrasound and CT scan are also employed in conjunction with other examinations for diagnosis of renal disorders [18]. Waist circumference measurements, height and body weight measurements are carried out to determine body mass index and classify obesity [19]. In addition, heart rate, blood pressure monitoring and biochemical assays to determine cortisol and thyroid function are also prescribed by clinicians to diagnose obesity [20].
Efforts to develop strategies for accurate measure of distinct biomarkers in each condition will enable more accurate diagnosis of MetS-associated complications. Concerted efforts to identify quantifiable parameters that truly reflect the magnitude and severity of MetS complications are underway. Sensors with biological recognition element for the detection analytes have been successfully employed for the analysis of biomarkers in recent years [21]. Such sensors are called ‘biosensors’ and they commonly employ antibodies, enzymes, oligonucleotides, aptamers and cells as the recognition element. The first biosensor that appeared in the market in 1974 was a glucose analyzer originally developed by Clarke and Lyons in 1962 which was based on the formation of gluconic acid and hydrogen peroxide from glucose by the recognition element which was an enzyme glucose oxidase [22]. The sensor was then described as ‘enzyme electrode’. Since then, rapid advances have been made in the field of biosensors and it has now become an indispensable aspect of clinical diagnostics.
The transducer output from the sensor could arise due to changes in the optical properties that include absorbance, fluorescence, reflectance, refractive index, luminescence and surface plasmon resonance (SPR) or electrochemical properties where the signal is generated as a result of electron transfer due to redox reactions involving the analyte [23]. Calorimetric sensors measure heat changes occurring due to the reactions involving the analyte while electrical sensors respond to changes in electrical resistance. Piezoelectric sensors employ pressure-sensitive elements that record minute changes in the mass on the sensing element and generate a corresponding electrical signal [23]. Newer transduction strategies based on magnetic transduction principles are also on the anvil [24].
Among the diverse sensor categories, optical and electrochemical transduction mechanisms have been widely explored for quantitative detection of clinically relevant markers. Electrochemical biosensors are superior than optical sensors as they produce a stable signal towards the analyte. Furthermore, the electrochemical sensor modification process is easy and also cost-effective [25]. Hence, this type of electrochemical biosensor forms the focus of our review. A literature search was performed using the keywords “multi-analyte detection, electrochemical sensors, biomarkers for metabolic syndrome, MetS” in the databases like Scopus, PubMed, Google Scholar and SciFinder. The relevant articles were chosen for the review.

4. Evolution of Electrochemical Biosensors

Electrochemical biosensors have been developed over the years in terms of their superior sensitivity, quick response time as well as the wide range of analyte molecules that can be detected easily using the surface modification process according to the analyte of interest. Figure 2 depicts the schematic representation of the different generations of electrochemical sensors developed over the years. The earliest electrochemical sensors known as the first-generation sensors quantified the analyte indirectly by measuring the accompanying changes in the hydrogen peroxide or oxygen concentrations. However, this strategy restricted the type of analytes that could be detected as well as that had lower sensitivity. As the redox site in most enzymes is buried deep in the interior, accessibility restrictions and slow electron transfer from the analyte are common in these types of sensors resulting in slow response time [8,14]. These limitations were overcome in the second-generation sensors that employed a redox mediator such as ferrocene or quinone to shuttle electrons from the bio-recognition element to the electrode surface. This strategy eliminates indirect measurement of the analyte and enables faster detection. However, use of a redox mediator for electron transfer makes these types of sensors prone to interference from other electro-active species in the sample. Furthermore, choice of an appropriate redox mediator is an added complexity in the sensing process [26]. Hence, the third-generation sensors employed a direct transfer of the electrons from the biorecognition element to the working electrode surface. To ensure rapid response and sensitivity in this type of sensors, intimate contact of the biorecognition site with the electrode surface is required. The immobilization of the biosensing element on the working electrode surface, therefore, acquires prime importance for efficient electron transfer. Both physical and chemical methods of immobilization have been reported. The interactions between the immobilized biomolecule and the electrode surface are generally hydrogen bonding, electrostatic, hydrophobic and dipole–dipole interactions. However, the third-generation sensors are limited by accessibility issues, diffusional limitations and denaturation risks of the biological sensing element [27]. Hence recent times have seen the emergence of a fourth generation of sensors which employ chemical entities that serve as bio mimics to overcome the stability issues associated with the immobilization of biological molecules on the electrode surface [28].
Multiple enzymes can be immobilized into each substrate present in the array which would enable the simultaneous detection of MetS biomarkers in a label-free approach. The advantage of these sensors will be quick response time and low sample volume compared to conventional sensors focusing on single analyte detection. However, matching the selectivity of biological molecules remains a major challenge in the bio-mimetic sensing elements. Instead of conventional electrodes researchers have attempted several strategies using screen-printed electrodes for the analysis of metabolites [29,30,31]. In recent years, response time of the electrochemical sensors has been improved by the incorporation of nanomaterials as interface between the electrode and enzyme surface. These nano materials further enhance the surface coverage as well as sensitivity resulting in low detection limits and low sample requirements [32]. A wide range of nanomaterials such as metal nanoparticles [33,34,35], metal oxide nanostructures [36,37,38,39,40,41,42,43,44,45,46], polymeric nanoparticles [47], carbon nanotubes [48,49,50,51], graphene [52,53,54,55,56], quantum dots [57,58,59,60,61], hydrogels [62,63,64,65,66], and ceramic nanostructures [67,68] have been extensively studied as interface materials in electrochemical nanosensors. The nano-dimensional interface in electrochemical sensors exhibits several unique characteristics. Their high surface area-to-volume ratio facilitates immobilization of larger number of biomolecules thereby improving the number of active sites on the electrode surface [69]. Metal and metal oxide nanoparticles were proved to enhance the electron transfer rate due of their tiny size and higher conductivity. Furthermore, the close contact between the nanoparticle and biomolecule improves the stability of the biosensor [32]. In several instances, metallic nanoparticles have been reported to serve as catalysts for the electrochemical reaction involving the analyte [70]. The introduction of more than one type of nanoparticle as interface material will further leads to the enhancement of biosensor properties in terms of wide linear range, quick response time and high sensitivity [71]. Such smart sensor systems with hybrid nano interfaces for multiple analyte detection will ensure for rapid and accurate analysis of biomarkers in the field of clinical diagnosis in the modern era.

5. Electrochemical Detection Strategies for Multi-Analyte Detection

Development of sensors for single analytes may not always be conclusive for diagnosis of a clinical anomaly, especially for MetS where co-existence of multiple complications necessitates the development of integrated systems that can simultaneously detect multiple analytes. Although there are plenty of reports available for single analyte detection, only a miniscule fraction of the literature is available for multi-analyte detection using electrochemical methods. As MetS is a constellation of disorders, a single biomarker is insufficient to diagnose it. Therefore, multi-analyte detection is required for diagnosis of MetS. Conventional diagnosis also uses multiple parameters to diagnose MetS. However, these parameters are subjective and less sensitive, thereby requiring multiple tests over an extended duration for diagnosis. The sensor arrays based on electrochemical detection and nano-interfaces can detect multiple biomarkers rapidly with high sensitivity. Fabrication of these sensors on disposable and cheap substrates like paper can enable affordable low-volume diagnosis and large-scale screening of populations for multiple dysfunctions associated with MetS such as elevated blood glucose levels, triglycerides, cholesterol levels, obesity, oxidative stress and hypertension. Electrochemical biosensors with highly specific detection capabilities eliminate interferences from other metabolites encountered in body fluids. A positive result for more than one marker in the panel indicates higher risk of MetS and the individual can then be referred for additional tests to confirm the preliminary diagnosis. Such early detection strategies can reduce mortality and improve quality of life. But, the current challenge is to identify the most relevant biomarkers that truly represent the risk of MetS and integration of these marker panels in a single array without compromising on the specificity as well as detection range. Another pitfall in such strategies is that they are invasive methods of diagnosis though the sample volume required may be low. However, the benefits of such interventions outweigh their limitations and hence such strategies can be invaluable in the near future for clinical applications.
Employment of hybrid nano-interface materials for multiple-analyte detection has been proved to improve sensor performance as well as reduce the response time [72,73]. The techniques like CV (cyclic voltammetry), Amp (amperometry), CA (Chronoamperometry), EIS (Electrochemical impedance spectroscopy) and DPV (differential pulse voltammetry) are among electrochemical methods that provide different information on the interactions between the analyte and sensing element at the electrode-electrolyte interface. CV is extensively employed technique in electrochemical sensors which gives insights in to the reaction that occurs at the electrode whereas DPV is a pulse technique with better sensitivity than CV. It displays a single pulse of either an oxidation or a reduction process occurring in the system on the introduction of the sample containing the analyte of interest. The amperometric technique is another sensitive method that monitors the current changes with time at a constant potential. The step-wise profile obtained in dynamic conditions provides information on the stability and the reproducibility of the system. Electrochemical impedance provides information on the capacitance changes at the electrode surface accompanying changes in the concentration of the analyte of interest. Choice of a technique therefore, depends on the combination of electrode, electrolyte, nanointerface and capture agent employed. The major contributor to improved sensitivity is from the nanointerface materials and the enzymes/antibodies used for specific detection while the contribution by advanced instrumentation and techniques are minimal.
Dopamine, a neurotransmitter, has been observed to be involved in the regulation of glucose and lipid metabolism, blood pressure and insulin release [74]. Obese individuals have been found to exhibit reduced levels of dopamine [75]. Obese individuals and diabetes-complicated individuals are also reported to have depleted levels of ascorbic acid [76,77]. Uric acid is a well-established marker for kidney disorders [78,79]. Hence, these analytes can be useful for prediction of MetS risk in individuals. A glassy carbon electrode (GCE) modified with ZnO was employed for the simultaneous detection of dopamine, ascorbic acid and uric acid [80] in the detection range of 6–960 µM,15–240 µM and 0.5–800 µM for dopamine (DA), ascorbic acid(AA) and uric acid (UA), respectively. Similarly, as shown in Figure 3D a combination of carbon black–carbon nanotube nano-interface and polyimide has been employed as a working electrode for the simultaneous sensing of AA, DA, and UA. This fabricated sensor showed the enhanced sensitivity to only two of the analyte’s DA and UA, with lowest detection limit of 1.9 µM and 3 µM respectively. Applicability of the sensor was tested in human urine samples with good recovery values [81]. Another sensor with a simplified interface comprising carbon black-chitosan mixture was tuned as a water soluble homogenous ink deposited on a GCE for concurrent detection of AA, UA and DA as shown in Figure 3A with a lower detection limit of 0.1 μM achieved for all the three analytes. Though not developed specifically for MetS, this sensor was tested in real samples such as vitamin C tablets for AA, dopamine chloride injection for DA, and human urine samples for UA, and has potential to be used as a MetS screening device [82].
Apart from glucose, glutamine and glutamate have been identified as key metabolites in glucose metabolism while lactate accumulation has been cited as a key indicator of metabolic disorders. A disposable electrochemical biosensor precalibrated in 1–5µL flow-through cell was fabricated for the simultaneous detection of glucose, lactate, glutamine and glutamate [83]. This sensor exhibited a detection range upto 5 mM for glucose, 2 mM for lactate, 1 mM for glutamine and 200 µM for glutamate. An electrochemical array chip based sensor has been developed for the simultaneous detection of glucose and lactate [79]. The working electrode of this sensor comprises iridium oxide. The electrochemical detection of glucose was linear between the concentrations of 5 mM and 10 mM while the linear range for lactate measurement was found to be 0–2 mM. Sol-gel based mesoporous silica combined with multiwalled carbon nanotubes (MWCNTs) was employed as a hybrid interface that was successfully employed for the detection of dopamine, uric acid and paracetamol in biological samples [84]. Though paracetamol is a drug that has no direct correlation with MetS, the dopamine and uric acid levels in the body provide important information about MetS-associated disorders. The working electrode used in this sensor was modified with a hybrid nano interface of SiO2 and multi walled carbon nanotubes. The detection range for uric acid, dopamine and paracetamol was found to be 0.6–4.65 µM, 0.13–4.64 µM and 0.67–4.65 µM, respectively. A bienzymatic sensor for the simultaneous detection of glucose (Glu) and cholesterol (ChL) has been designed using polythionine and gold nanoparticles incorporated between the enzymes glucose oxidase and cholesterol oxidase on a glassy carbon electrode [85]. The amperometric measurement of glucose and cholesterol in the samples was achieved in the concentrations of 0.008–6 mM and 0.002–1 mM respectively. It has been shown that the use of iron oxide nano particles enhances the binding efficiency of the enzyme cholesterol oxidase for the detection of cholesterol and glucose oxidase for glucose detection [86]. Along similar lines, a low-cost biosensor for monitoring the glucose (Glu), UA, and cholesterol (ChL) simultaneously was fabricated using a flexible microneedle electrode consisting of gold/titanium film on the surface along with electrodeposited polyaniline nanofibers/platinum nanoparticles for electron transfer and respective enzymes on the modified film. Samples were prepared by spiking known amounts of Glu, UA and ChL in fetal bovine serum albumin and detected using amperometric technique. The reported microneedle sensor enables self-health monitoring of blood metabolites by using minimally invasive microneedles that permeate up to the dermal layer of the skin [87]. A multi-analyte sensor for the detection of seven analytes namely, H2O2, lactate, NADH (reduced nicotinamide adenine dinucleotide), ascorbic acid, uric acid, nitrite and dopamine was fabricated with a hybrid interface of iron oxide nanoparticles and reduced graphene oxide nanosheets on an indium tin oxide electrode [88]. While the role of H2O2, lactate, ascorbic acid, uric acid and dopamine in MetS-related disorders have already been identified, NADH being a key co-enzyme in glucose and lipid metabolic pathways are important indicators of the metabolic regulation in an individual [89]. Similarly, it has been demonstrated that reduced nitrite and nitrate levels contribute to endothelial dysfunction and MetS [90]. The amperometric measurement of each analyte was accomplished at specific potentials of −0.3 V (H2O2), +0.01 V (ascorbic acid), +0.1 V (lactate), +0.05 V (NADH), +0.33 V (uric acid), +0.16 V (dopamine) and +0.7 V (nitrite). The sensor was able to quantify lactate levels between 0. 2 µM and 2.2 mM, uric acid levels in the range4–20 µM, ascorbic acid in the sample between 160 µM and 7.2 mM, dopamine concentrations of0.4–3.5 µM, H2O2 concentrations between 20 nM and 0.28 µM, nitrite and NADH levels in the range 20–210 µM and 2–15 µM respectively [88]. Magnetite nanoparticles coated with polydopamine were covalently attached to glucose oxidase as shown in Figure 3E was employed for the analysis of glucose in human serum samples [89].In another interesting work, molybdenum disulphide (MoS2) nanosheets supported Au–Pd bimetallic nanoparticles were employed for the enzyme-free sensing of glucose and H2O2 as indicated in Figure 3B. This non-enzymatic sensor exhibited a wide linear range of 0.8 μM–10 mM for H2O2 and 0.5–20 mM for glucose [91]. As shown in Figure 3C glucose and uric acid were simultaneously monitored using screen printed strip-based electrode with dual channels. One channel was modified with glucose oxidase and the second channel is modified with uric acid oxidase for specific detection of glucose and uric acid simultaneously from a single sample [92]. Several attempts to develop sensors for the quantification of glucose and hydrogen peroxide are reported in literature. Palladium-cobalt nanoparticles over carbon nanotubes using one-pot synthesis method was reported by Huang et al. as shown in Figure 3F [93].
An electrochemical biosensor comprising nanoporous nanosponge architecture of Pd–Cu alloy fabricated by etching off Al from PdCuAl alloy was employed for the detection of glucose and H2O2. This enzyme-free sensor exhibited long-term stability, high sensitivity and wide linear range of 1–30 mM for glucose and 0.1–2 mM for H2O2 [94]. Electrospun Co3O4 nanofibers were used for electrochemical analysis of glucose and H2O2 by cyclic voltammetry, chronoamperometry and impedance analysis in an alkaline medium of 0.1 M NaOH as supporting electrolyte. The sensor exhibited a short response time ~1.5 s for glucose and 6.6 s for H2O2 and a linear range of 50–1000 µM and 20–400 µM for glucose and H2O2, respectively [95]. A novel electrodeposition method was employed for the synthesis of snowflake-like Pt–Pd bimetallic nano-clusters on screen-printed gold nano film electrode (SPGFE). This enzyme less sensor was employed for the simultaneous detection and quantification of glucose and H2O2 [30]. The sensor performed well in the concentrations 0–16 mM for glucose and 0.005–6 mM for H2O2. An amperometric biosensor array comprising of phenylenediamine modified transducers was fabricated for the detection of choline, glutamate, glucose, lactate, acetylcholine and pyruvate in CSF (cerebrospinal fluid) and blood plasma within a minute and exhibiting a linear range prevailing between 0.001–0.01 and 0.2–2.5mM and limit of detection (LOD) of 1–5 µM [96]. Several other combinations of nanointerfaces and electrode materials have been reported for the detection of glucose and H2O2 that are summarized in Table 3. All these sensors are still in the research phase and are yet to be deployed in a clinical set-up. It also lists the details of electrochemical sensors reported for sensing of multiple analytes since 2008 for biomarkers associated with MetS complications. Although each component in some combinations such as acetaminophen and codeine are not directly associated with MetS, the other analytes detected in the combination provide insights in to the severity of MetS disorders in the individual.

6. Conclusions and Future Directions

Metabolic syndrome is rapidly emerging as a major health risk in the world. Effective and rapid diagnosis of this condition requires multi-analyte detection. Electrochemical sensors have emerged as a major tool for rapid monitoring of disease markers. Although these sensors have not been specifically designed for diagnosis of metabolic syndrome, their efficiency in detecting the biomarkers that are associated with some of the complications currently identified as part of metabolic syndrome suggests that these sensors could usher in superior devices for diagnosis of metabolic syndrome. Although the importance of multi-analyte detection has been recognized, not many effective sensor panels have been developed for diagnosis of MetS complications. The scan of literature reveals several interesting attempts to fabricate multi-analyte electrochemical sensors employing different types of nanointerface and biological-sensing elements. Therefore, development of sensor arrays employing an intelligent combination of nanointerfaces, enzymes and electrode fabrication for specific detection of key markers from biological fluids that can predict the risk of MetS is of current importance. Currently, this field is in its infancy and further innovations in development of sensor arrays for quantification of specific markers associated with MetS is on the anvil in coming decades. Recent advances in fabrication of low-cost and disposable electrodes using 3D printing and screen-printing methods, and use of machine learning and artificial intelligence to predict MetS associated complications could be a game changer in the future for large-scale screening of populations.

Author Contributions

M.S. collected the literatures and wrote the manuscript. K.S.S.D. compiled the figures and tables. J.K.B. has supported in formatting the references. J.B.B.R. gave inputs and corrected the manuscript. U.M.K. conceptualized the idea and corrected the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

Madhurantakam Sasya pleased to acknowledge Department of Science and Technology for INSPIRE Fellowship (DST/IF/120812) and Japan Society for the Promotion of Science for JSPS Postdoctoral Fellowship (P18411). Uma Maheswari Krishnan and K. S. Shalini Devi wish to acknowledge RCUK grant (MR/P027881/1) for the financial support.

Acknowledgments

Authors wish to acknowledge SASTRA Deemed-to-be University for financial and infrastructural support.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Robbins, G.R.; Wen, H.; Ting, J.P.Y. Inflammasomes and metabolic disorders: Old genes in modern diseases. Mol. Cell 2014, 54, 297–308. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. What Is Metabolic Syndrome? National Heart, Lung, and Blood Institute: Bethesda, MD, USA, 2016.
  3. Oladejo, A.O. Overview of the metabolic syndrome; an emerging pandemic of public health significance. Ann. Ib. Postgrad. Med. 2011, 9, 78–82. [Google Scholar] [PubMed]
  4. Alberti, K.G.M.M.; Zimmet, P.; Shaw, J. The metabolic syndrome—A new worldwide definition. Lancet 2005, 366, 1059–1062. [Google Scholar] [CrossRef]
  5. Sarafidis, P.A.; Nilsson, P.M. The metabolic syndrome: A glance at its history. J. Hypertens. 2006, 24, 621–626. [Google Scholar] [CrossRef] [PubMed]
  6. Oda, E. Metabolic syndrome: Its history, mechanisms, and limitations. Acta Diabetol. 2012, 49, 89–95. [Google Scholar] [CrossRef]
  7. Eckel, R.H.; Alberti, K.G.M.M.; Grundy, S.M.; Zimmet, P.Z. The metabolic syndrome. Lancet 2010, 365, 1–72. [Google Scholar] [CrossRef]
  8. Bonomini, F.; Rodella, L.F.; Rezzani, R. Metabolic Syndrome, Aging and Involvement of Oxidative Stress. Aging Dis. 2015, 6, 109. [Google Scholar] [CrossRef] [Green Version]
  9. Park, Y.; Zhu, S.; Palaniappan, L.; Heshka, S. The Metabolic Syndrome. Arch. Intern. Med. 2003, 163, 427–436. [Google Scholar] [CrossRef] [Green Version]
  10. Koroshi, A. Microalbuminuria, is it so important? Hippokratia 2007, 11, 105–107. [Google Scholar]
  11. Patel, J.L.; Suthar, A.M.; Dalsaniya, V.B.; Parikh, A.P.; Suthar, N.N.; Patel, K.L. A study of metabolic syndrome and its components in Type 2 Diabetes Mellitus subjects and their asymptomatic First degree relatives. Indian J. Clin. Pract. 2013, 23, 520–533. [Google Scholar]
  12. Verma, S.; Hussain, M.E. Obesity and diabetes: An update. Diabetes Metab. Syndr. Clin. Res. Rev. 2017, 11, 73–79. [Google Scholar] [CrossRef] [PubMed]
  13. Grundy, S.M. Metabolic syndrome: A multiplex cardiovascular risk factor. J. Clin. Endocrinol. Metab. 2007, 92, 399–404. [Google Scholar] [CrossRef] [PubMed]
  14. Yazdanpanah, S.; Rabiee, M.; Tahriri, M.; Abdolrahim, M.; Tayebi, L. Glycated hemoglobin-detection methods based on electrochemical biosensors. TrAC Trends Anal. Chem. 2015, 72, 53–67. [Google Scholar] [CrossRef]
  15. Heart online. Common Investigations In Cardiovascular Disease. Blood tests Full Blood Count (FBC). 2014, pp. 1–3. Available online: https://www.heartonline.org.au/media/DRL/Investigations_in_cardiovascular_disease.pdf (accessed on 6 December 2019).
  16. Leaf, D.A. Hypertriglyceridemia: A Guide to Assessment and Treatment. Hosp. Physician 2008, 32, 17–24. [Google Scholar]
  17. Laterza, O.F.; Price, C.P.; Scott, M.G. Cystatin C: An improved estimator of glomerular filtration rate? Clin. Chem. 2002, 48, 699–707. [Google Scholar]
  18. Herget-Rosenthal, S. Imaging Techniques in the Management of Chronic Kidney Disease: Current Developments and Future Perspectives. Semin. Nephrol. 2011, 31, 283–290. [Google Scholar] [CrossRef]
  19. Sangachin, M.G.; Cavuoto, L.A.; Wang, Y. Use of various obesity measurement and classification methods in occupational safety and health research: a systematic review of the literature. BMC Obes. 2018, 5, 28. [Google Scholar] [CrossRef]
  20. Douyon, L.; Schteingart, D.E. Effect of obesity and starvation on thyroid hormone, growth hormone, and cortisol secretion. Endocrinol. Metab. Clin. N. Am. 2002, 31, 173–189. [Google Scholar] [CrossRef]
  21. Yoo, E.-H.; Lee, S.-Y. Glucose Biosensors: An Overview of Use in Clinical Practice. Sensors 2010, 10, 4558–4576. [Google Scholar] [CrossRef] [Green Version]
  22. Monošík, R.; Streďanský, M.; Šturdík, E. Biosensors—Classification, characterization and new trends. Acta Chim. Slovaca 2012, 5, 109–120. [Google Scholar] [CrossRef] [Green Version]
  23. Justino, C.I.L.; Duarte, A.C.; Rocha-Santos, T.A.P. Critical overview on the application of sensors and biosensors for clinical analysis. TrAC Trends Anal. Chem. 2016, 85, 36–60. [Google Scholar] [CrossRef]
  24. Palchetti, I.; Mascini, M.; Chimica, D.; Lastruccia, V. Biosensor Technology: A Brief History. In Sensors and Microsystems; Springer: Dordrecht, The Netherlands, 2010; Volume 54, pp. 15–23. [Google Scholar]
  25. Qureshi, A.; Gurbuz, Y.; Niazi, J.H. Biosensors for cardiac biomarkers detection: A review. Sens. Actuators B Chem. 2012, 171–172, 62–76. [Google Scholar] [CrossRef] [Green Version]
  26. Park, S.; Boo, H.; Chung, T.D. Electrochemical non-enzymatic glucose sensors. Anal. Chim. Acta 2006, 556, 46–57. [Google Scholar] [CrossRef] [PubMed]
  27. Murugaiyan, S.B.; Ramasamy, R.; Gopal, N.; Kuzhandaivelu, V. Biosensors in clinical chemistry: An overview. Adv. Biomed. Res. 2014, 3, 67. [Google Scholar]
  28. Holade, Y.; Tingry, S.; Servat, K.; Napporn, T.; Cornu, D.; Kokoh, K. Nanostructured Inorganic Materials at Work in Electrochemical Sensing and Biofuel Cells. Catalysts 2017, 7, 31. [Google Scholar] [CrossRef] [Green Version]
  29. Milano, F.; Giotta, L.; Chirizzi, D.; Papazoglou, S.; Kryou, C.; De Bartolomeo, A.; De Leo, V.; Guascito, M.R.; Zergioti, I. Phosphate modified screen printed electrodes by lift treatment for glucose detection. Biosensors 2018, 8, 91. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  30. Niu, X.; Chen, C.; Zhao, H.; Chai, Y.; Lan, M. Novel snowflake-like Pt-Pd bimetallic clusters on screen-printed gold nanofilm electrode for H2O2 and glucose sensing. Biosens. Bioelectron. 2012, 36, 262–266. [Google Scholar] [CrossRef]
  31. Kimmel, D.W.; LeBlanc, G.; Meschievitz, M.E.; Cliffel, D.E. Chemical Sensors and Biosensors. Anal. Chem. 2007, 84, 685–707. [Google Scholar] [CrossRef] [Green Version]
  32. Asefa, T.; Duncan, C.T.; Sharma, K.K. Recent advances in nanostructured chemosensors and biosensors. Analyst 2009, 134, 1980–1990. [Google Scholar] [CrossRef]
  33. Chen, S.; Yuan, R.; Chai, Y.; Hu, F. Electrochemical sensing of hydrogen peroxide using metal nanoparticles: A review. Microchim. Acta 2012, 180, 15–32. [Google Scholar] [CrossRef]
  34. Chauhan, N.; Chawla, S.; Pundir, C.S.; Jain, U. An electrochemical sensor for detection of neurotransmitter-acetylcholine using metal nanoparticles, 2D material and conducting polymer modified electrode. Biosens. Bioelectron. 2017, 89, 377–383. [Google Scholar] [CrossRef]
  35. Zeng, Q.; Cheng, J.S.; Liu, X.F.; Bai, H.T.; Jiang, J.H. Palladium nanoparticle/chitosan-grafted graphene nanocomposites for construction of a glucose biosensor. Biosens. Bioelectron. 2011, 26, 3456–3463. [Google Scholar] [CrossRef] [PubMed]
  36. Lin, C.-Y.; Chang, C.-T. Iron oxide nanorods array in electrochemical detection of H2O2. Sens. Actuators B Chem. 2015, 220, 695–704. [Google Scholar] [CrossRef]
  37. Ibupoto, Z.; Khun, K.; Beni, V.; Willander, M. Non-Enzymatic Glucose Sensor Based on the Novel Flower Like Morphology of Nickel Oxide. Soft Nanosci. Lett. 2013, 3, 46–50. [Google Scholar] [CrossRef] [Green Version]
  38. Guascito, M.R.; Chirizzi, D.; Malitesta, C.; Siciliano, T.; Tepore, A. Te oxide nanowires as advanced materials for amperometric nonenzymatic hydrogen peroxide sensing. Talanta 2013, 115, 863–869. [Google Scholar] [CrossRef] [PubMed]
  39. Marie, M.; Mandal, S.; Manasreh, O. An Electrochemical Glucose Sensor Based on Zinc Oxide Nanorods. Sensors 2015, 15, 18714–18723. [Google Scholar] [CrossRef] [PubMed]
  40. Ma, Y.; Di, J.; Yan, X.; Zhao, M.; Lu, Z.; Tu, Y. Direct electrodeposition of gold nanoparticles on indium tin oxide surface and its application. Biosens. Bioelectron. 2009, 24, 1480–1483. [Google Scholar] [CrossRef] [PubMed]
  41. Wang, J.X.; Sun, X.W.; Wei, A.; Lei, Y.; Cai, X.P.; Li, C.M.; Dong, Z.L. Zinc oxide nanocomb biosensor for glucose detection. Appl. Phys. Lett. 2006, 88. [Google Scholar] [CrossRef]
  42. Wu, W.; He, Q.; Jiang, C. Magnetic iron oxide nanoparticles: Synthesis and surface functionalization strategies. Nanoscale Res. Lett. 2008, 3, 397–415. [Google Scholar] [CrossRef] [Green Version]
  43. Kaushik, A.; Solanki, P.R.; Ansari, A.A.; Sumana, G.; Ahmad, S.; Malhotra, B.D. Iron oxide-chitosan nanobiocomposite for urea sensor. Sens. Actuators B Chem. 2009, 138, 572–580. [Google Scholar] [CrossRef]
  44. Batchelor-McAuley, C.; Wildgoose, G.G.; Compton, R.G.; Shao, L.; Green, M.L.H. Copper oxide nanoparticle impurities are responsible for the electroanalytical detection of glucose seen using multiwalled carbon nanotubes. Sens. Actuators B Chem. 2008, 132, 356–360. [Google Scholar] [CrossRef]
  45. Vabbina, P.K.; Kaushik, A.; Pokhrel, N.; Bhansali, S.; Pala, N. Electrochemical cortisol immunosensors based on sonochemically synthesized zinc oxide 1D nanorods and 2D nanoflakes. Biosens. Bioelectron. 2015, 63, 124–130. [Google Scholar] [CrossRef] [PubMed]
  46. Hahn, Y.-B.; Ahmad, R.; Tripathy, N. Chemical and biological sensors based on metal oxide nanostructures. Chem. Commun. 2012, 48, 10369. [Google Scholar] [CrossRef] [PubMed]
  47. Ates, M. A review study of (bio)sensor systems based on conducting polymers. Mater. Sci. Eng. C 2013, 33, 1853–1859. [Google Scholar] [CrossRef] [PubMed]
  48. Dhand, C.; Solanki, P.R.; Datta, M.; Malhotra, B.D. Polyaniline/Single-Walled Carbon Nanotubes Composite Based Triglyceride Biosensor. Electroanalysis 2010, 22, 2683–2693. [Google Scholar] [CrossRef]
  49. Jeykumari, D.R.S.; Narayanan, S.S. Functionalized carbon nanotube-bienzyme biocomposite for amperometric sensing. Carbon N.Y. 2009, 47, 957–966. [Google Scholar] [CrossRef]
  50. Sotiropoulou, S.; Chaniotakis, N.A. Carbon nanotube array-based biosensor. Anal. Bioanal. Chem. 2003, 375, 103–105. [Google Scholar] [CrossRef]
  51. Rivas, G.A.; Rubianes, M.D.; Rodríguez, M.C.; Ferreyra, N.F.; Luque, G.L.; Pedano, M.L.; Miscoria, S.A.; Parrado, C. Carbon nanotubes for electrochemical biosensing. Talanta 2007, 74, 291–307. [Google Scholar] [CrossRef]
  52. Electrochemical, O.N. Graphene and Other Nanomaterial-Based Electrochemical Aptasensors. Biosensors 2012, 2, 1–14. [Google Scholar]
  53. Kumar, V.; Shorie, M.; Ganguli, A.K.; Sabherwal, P. Graphene-CNT nanohybrid aptasensor for label free detection of cardiac biomarker myoglobin. Biosens. Bioelectron. 2015, 72, 56–60. [Google Scholar] [CrossRef]
  54. Artiles, M.S.; Rout, C.S.; Fisher, T.S. Graphene-based hybrid materials and devices for biosensing. Adv. Drug Deliv. Rev. 2011, 63, 1352–1360. [Google Scholar] [CrossRef]
  55. Zhang, X.; Liao, Q.; Chu, M.; Liu, S.; Zhang, Y. Structure effect on graphene-modified enzyme electrode glucose sensors. Biosens. Bioelectron. 2014, 52, 281–287. [Google Scholar] [CrossRef] [PubMed]
  56. Liu, Y.; Dong, X.; Chen, P. Biological and chemical sensors based on graphene materials. Chem. Soc. Rev. 2012, 41, 2283. [Google Scholar] [CrossRef] [PubMed]
  57. Zhao, J.; Chen, G.; Zhu, L.; Li, G. Graphene quantum dots-based platform for the fabrication of electrochemical biosensors. Electrochem. Commun. 2011, 13, 31–33. [Google Scholar] [CrossRef]
  58. Razmi, H.; Mohammad-Rezaei, R. Graphene quantum dots as a new substrate for immobilization and direct electrochemistry of glucose oxidase: Application to sensitive glucose determination. Biosens. Bioelectron. 2013, 41, 498–504. [Google Scholar] [CrossRef]
  59. Han, E.; Yang, Y.; He, Z.; Cai, J.; Zhang, X.; Dong, X. Development of tyrosinase biosensor based on quantum dots/chitosan nanocomposite for detection of phenolic compounds. Anal. Biochem. 2015, 486, 102–106. [Google Scholar] [CrossRef]
  60. Chen, Z.; Ren, X.; Meng, X.; Chen, D.; Yan, C.; Ren, J.; Yuan, Y.; Tang, F. Optical detection of choline and acetylcholine based on H2O2-sensitive quantum dots. Biosens. Bioelectron. 2011, 28, 50–55. [Google Scholar] [CrossRef]
  61. Khan, S.A.; Smith, G.T.; Seo, F.; Ellerbee, A.K. Label-free and non-contact optical biosensing of glucose with quantum dots. Biosens. Bioelectron. 2015, 64, 30–35. [Google Scholar] [CrossRef]
  62. Li, L.; Wang, Y.; Pan, L.; Shi, Y.; Cheng, W.; Shi, Y.; Yu, G. A Nanostructured Conductive Hydrogels-Based Biosensor Platform for Human Metabolite Detection. Nano Lett. 2015, 15. [Google Scholar] [CrossRef]
  63. Kestwal, R.M.; Bagal-Kestwal, D.; Chiang, B.-H. Fenugreek hydrogel-agarose composite entrapped gold nanoparticles for acetylcholinesterase based biosensor for carbamates detection. Anal. Chim. Acta 2015, 886, 143–150. [Google Scholar] [CrossRef]
  64. Liu, A.; Chen, X.; Wang, K.; Wei, N.; Sun, Z.; Lin, X.; Chen, Y.; Du, M. Electrochemical DNA biosensor based on aldehyde-agarose hydrogel modified glassy carbon electrode for detection of PML/RARa fusion gene. Sens. Actuators B Chem. 2011, 160, 1458–1463. [Google Scholar] [CrossRef]
  65. Buenger, D.; Topuz, F.; Groll, J. Hydrogels in sensing applications. Prog. Polym. Sci. 2012, 37, 1678–1719. [Google Scholar] [CrossRef]
  66. Song, H.S.; Kwon, O.S.; Kim, J.H.; Conde, J.; Artzi, N. 3D hydrogel scaffold doped with 2D graphene materials for biosensors and bioelectronics. Biosens. Bioelectron. 2017, 89, 187–200. [Google Scholar] [CrossRef] [PubMed]
  67. Razmi, H.; Habibi, E. Nanomolar detection of hydrogen peroxide at a new polynuclear cluster of tin pentacyanonitrosylferrate nanoparticle-modified carbon ceramic electrode. Anal. Biochem. 2009, 392, 126–132. [Google Scholar] [CrossRef] [PubMed]
  68. Warsinke, A. Point-of-care testing of proteins. Anal. Bioanal. Chem. 2009, 393, 1393–1405. [Google Scholar] [CrossRef] [PubMed]
  69. Luo, X.; Morrin, A.; Killard, A.J.; Smyth, M.R. Application of nanoparticles in electrochemical sensors and biosensors. Electroanalysis 2006, 18, 319–326. [Google Scholar] [CrossRef] [Green Version]
  70. Hayat, A.; Catanante, G.; Marty, J.L. Current trends in nanomaterial-based amperometric biosensors. Sensors 2014, 14, 23439–23461. [Google Scholar] [CrossRef] [Green Version]
  71. Madhurantakam, S.; Jayanth Babu, K.; Balaguru Rayappan, J.B.; Krishnan, U.M. Fabrication of mediator-free hybrid nano-interfaced electrochemical biosensor for monitoring cancer cell proliferation. Biosens. Bioelectron. 2017, 87, 832–841. [Google Scholar] [CrossRef]
  72. Larin, A.; Womble, P.C.; Dobrokhotov, V. Hybrid SnO2/TiO2 nanocomposites for selective detection of ultra-low hydrogen sulfide concentrations in complex backgrounds. Sensors 2016, 16, 1373. [Google Scholar] [CrossRef]
  73. Zhu, C.; Yang, G.; Li, H.; Du, D.; Lin, Y. Electrochemical Sensors and Biosensors Based on Nanomaterials and Nanostructures. Anal. Chem. 2015, 87, 230–249. [Google Scholar] [CrossRef]
  74. Pijl, H.; Romijn, J.A. Obesity, dopamine and the metabolic syndrome: Potential of dopaminergic agents in the control of metabolism. Curr. Opin. Endocrinol. Diabetes 2006, 13, 179–184. [Google Scholar] [CrossRef]
  75. Wang, G.J.; Volkow, N.D.; Logan, J.; Pappas, N.R.; Wong, C.T.; Zhu, W.; Netusil, N.; Fowler, J.S. Brain dopamine and obesity. Lancet 2001, 357, 354–357. [Google Scholar] [CrossRef]
  76. Limberg, J.K.; Kellawan, J.M.; Harrell, J.W.; Johansson, R.E.; Eldridge, M.W.; Proctor, L.T.; Sebranek, J.J.; Schrage, W.G. Exercise-mediated vasodilation in human obesity and metabolic syndrome: Effect of acute ascorbic acid infusion. AJP Heart Circ. Physiol. 2014, 307, H840–H847. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  77. Ellulu, M.S.; Rahmat, A.; Patimah, I.; Khaza’Ai, H.; Abed, Y. Effect of vitamin C on inflammation and metabolic markers in hypertensive and/or diabetic obese adults: A randomized controlled trial. Drug Des. Devel. Ther. 2015, 9, 3405–3412. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  78. Johnson, R.J.; Nakagawa, T.; Jalal, D.; Sánchez-Lozada, L.G.; Kang, D.H.; Ritz, E. Uric acid and chronic kidney disease: Which is chasing which? Nephrol. Dial. Transplant. 2013, 28, 2221–2228. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  79. Mohandas, R.; Johnson, R.J. Uric Acid Levels Increase Risk for New-Onset Kidney Disease. J. Am. Soc. Nephrol. 2008, 19, 2251–2253. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  80. Tang, C.F.; Kumar, S.A.; Chen, S.M. Zinc oxide/redox mediator composite films-based sensor for electrochemical detection of important biomolecules. Anal. Biochem. 2008, 380, 174–183. [Google Scholar] [CrossRef]
  81. Wang, Y.; Yang, T.; Hasebe, Y.; Zhang, Z.; Tao, D. Carbon black-carbon nanotube co-doped polyimide sensors for simultaneous determination of ascorbic acid, uric acid, and dopamine. Materials 2018, 11, 1691. [Google Scholar] [CrossRef] [Green Version]
  82. Dinesh, B.; Saraswathi, R.; Senthil Kumar, A. Water based homogenous carbon ink modified electrode as an efficient sensor system for simultaneous detection of ascorbic acid, dopamine and uric acid. Electrochim. Acta 2017, 233, 92–104. [Google Scholar] [CrossRef]
  83. Moser, I.; Jobst, G. Pre-calibrated biosensors for single-use applications. Chemie-Ingenieur-Technik 2013, 85, 172–178. [Google Scholar] [CrossRef]
  84. Canevari, T.C.; Raymundo-Pereira, P.A.; Landers, R.; Benvenutti, E.V.; Machado, S.A.S. Sol-gel thin-film based mesoporous silica and carbon nanotubes for the determination of dopamine, uric acid and paracetamol in urine. Talanta 2013, 116, 726–735. [Google Scholar] [CrossRef] [Green Version]
  85. Huang, Q.; An, Y.; Tang, L.; Jiang, X.; Chen, H.; Bi, W.; Wang, Z.; Zhang, W. A dual enzymatic-biosensor for simultaneous determination of glucose and cholesterol in serum and peritoneal macrophages of diabetic mice: Evaluation of the diabetes-accelerated atherosclerosis risk. Anal. Chim. Acta 2011, 707, 135–141. [Google Scholar] [CrossRef] [PubMed]
  86. Kouassi, G.K.; Irudayaraj, J.; McCarty, G. Activity of glucose oxidase functionalized onto magnetic nanoparticles. Biomagn. Res. Technol. 2005, 3, 1. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  87. Gao, J.; Huang, W.; Chen, Z.; Yi, C.; Jiang, L. Simultaneous detection of glucose, uric acid and cholesterol using flexible microneedle electrode array-based biosensor and multi-channel portable electrochemical analyzer. Sens. Actuators B Chem. 2019, 287, 102–110. [Google Scholar] [CrossRef]
  88. Teymourian, H.; Salimi, A.; Khezrian, S. Fe3O4 magnetic nanoparticles/reduced graphene oxide nanosheets as a novel electrochemical and bioeletrochemical sensing platform. Biosens. Bioelectron. 2013, 49, 1–8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  89. Jaime, J.; Rangel, G.; Muñoz-Bonilla, A.; Mayoral, A.; Herrasti, P. Magnetite as a platform material in the detection of glucose, ethanol and cholesterol. Sens. Actuators B Chem. 2017, 238, 693–701. [Google Scholar] [CrossRef]
  90. Mahjoub, S.; Masrour-Roudsari, J. Role of oxidative stress in pathogenesis of metabolic syndrome. Caspian J. Intern. Med. 2012, 3, 386–396. [Google Scholar]
  91. Li, X.; Du, X. Molybdenum disulfide nanosheets supported Au-Pd bimetallic nanoparticles for non-enzymatic electrochemical sensing of hydrogen peroxide and glucose. Sens. Actuators B Chem. 2017, 239, 536–543. [Google Scholar] [CrossRef]
  92. Guo, J.; Ma, X. Simultaneous Monitoring of Glucose and Uric Acid On a Single Test Strip with Dual Channels. Biosens. Bioelectron. 2017, 94, 415–419. [Google Scholar] [CrossRef]
  93. Huang, B.; Wang, Y.; Lu, Z.; Du, H.; Ye, J. One pot synthesis of palladium-cobalt nanoparticles over carbon nanotubes as a sensitive non-enzymatic sensor for glucose and hydrogen peroxide detection. Sens. Actuators B Chem. 2017, 252, 1016–1025. [Google Scholar] [CrossRef]
  94. Yang, H.; Wang, Z.; Li, C.; Xu, C. Nanoporous PdCu alloy as an excellent electrochemical sensor for H2O2 and glucose detection. J. Colloid Interface Sci. 2017, 491, 321–328. [Google Scholar] [CrossRef]
  95. George, G.; Anandhan, S. Tuning characteristics of Co3O4 nanofiber mats developed for electrochemical sensing of glucose and H2O2. Thin Solid Films 2016, 610, 48–57. [Google Scholar] [CrossRef]
  96. Kucherenko, D.Y.; Kucherenko, I.S.; Soldatkin, O.O.; Topolnikova, Y.V.; Dzyadevych, S.V.; Soldatkin, A.P. A highly selective amperometric biosensor array for the simultaneous determination of glutamate, glucose, choline, acetylcholine, lactate and pyruvate. Bioelectrochemistry 2019, 128, 100–108. [Google Scholar] [CrossRef] [PubMed]
  97. Zhang, L.; Li, H.; Ni, Y.; Li, J.; Liao, K.; Zhao, G. Porous cuprous oxide microcubes for non-enzymatic amperometric hydrogen peroxide and glucose sensing. Electrochem. Commun. 2009, 11, 812–815. [Google Scholar] [CrossRef]
  98. Wu, S.; Zhao, H.; Ju, H.; Shi, C.; Zhao, J. Electrodeposition of silver-DNA hybrid nanoparticles for electrochemical sensing of hydrogen peroxide and glucose. Electrochem. Commun. 2006, 8, 1197–1203. [Google Scholar] [CrossRef]
  99. Zhao, C.; Wu, X.; Li, P.; Zhao, C.; Qian, X. Hydrothermal deposition of CuO/rGO/Cu2O nanocomposite on copper foil for sensitive nonenzymatic voltammetric determination of glucose and hydrogen peroxide. Microchim. Acta 2017, 184, 2341–2348. [Google Scholar] [CrossRef]
  100. Liu, A.; Lang, Q.; Liang, B.; Shi, J. Sensitive detection of maltose and glucose based on dual enzyme-displayed bacteria electrochemical biosensor. Biosens. Bioelectron. 2017, 87, 25–30. [Google Scholar] [CrossRef]
  101. Gao, Z.F.; Chen, D.M.; Lei, J.L.; Luo, H.Q.; Li, N.B. A regenerated electrochemical biosensor for label-free detection of glucose and urea based on conformational switch of i-motif oligonucleotide probe. Anal. Chim. Acta 2015, 897, 10–16. [Google Scholar] [CrossRef]
  102. He, J.; Sunarso, J.; Zhu, Y.; Zhong, Y.; Miao, J.; Zhou, W.; Shao, Z. High-performance non-enzymatic perovskite sensor for hydrogen peroxide and glucose electrochemical detection. Sens. Actuators B Chem. 2017, 244, 482–491. [Google Scholar] [CrossRef]
  103. Wu, W.; Yu, B.; Wu, H.; Wang, S.; Xia, Q.; Ding, Y. Synthesis of tremella-like CoS and its application in sensing of hydrogen peroxide and glucose. Mater. Sci. Eng. C 2017, 70, 430–437. [Google Scholar] [CrossRef]
  104. Liu, M.; Liu, R.; Chen, W. Graphene wrapped Cu2O nanocubes: Non-enzymatic electrochemical sensors for the detection of glucose and hydrogen peroxide with enhanced stability. Biosens. Bioelectron. 2013, 45, 206–212. [Google Scholar] [CrossRef]
  105. Kumar-Krishnan, S.; de Fuentes, O.A.; Prokhorov, E.; Luna-Barcenas, J.G. Electrochemical detection of hydrogen peroxide and glucose based on chitosan stabilized silver nanowire modified electrodes. In Proceedings of the 2014 IEEE 9th IberoAmerican Congress on Sensors, Bogota, Colombia, 15–18 October 2014; pp. 5–8. [Google Scholar]
  106. Zhang, Y.; Zhou, Q.; Zhao, W.; Chu, W.; Zheng, J. Array of recessed gold nanoelectrodes formed with polymethylmethacrylate for individual detection of ascorbic acid, dopamine and uric acid. Electrochim. Acta 2016, 212, 25–31. [Google Scholar] [CrossRef]
  107. Jin, J.; Liu, W.; Deng, S.; Han, Y.; Cai, Y.; Hui, G. A non-enzyme electrochemical qualitative and quantitative analyzing method for glucose, D-fructose, and sucrose utilizing Cu foam material. Electrochim. Acta 2015, 153, 594–601. [Google Scholar] [CrossRef]
Sensors 20 00103 g001 550
Figure 1. Schematic representation of the risk factors for metabolic syndrome.
Figure 1. Schematic representation of the risk factors for metabolic syndrome.
Sensors 20 00103 g001
Sensors 20 00103 g002 550
Figure 2. Schematic representation of various generations of electrochemical sensors.
Figure 2. Schematic representation of various generations of electrochemical sensors.
Sensors 20 00103 g002
Sensors 20 00103 g003 550
Figure 3. Schematic representation of different modification processes of working electrodes utilizing different nanomaterials (A) carbon black [82] Copyright © 2017 Elsevier, (B) molybdenum disulphide (MoS2) nanosheets [91] Copyright © 2017 Elsevier, (C) enzyme modified screen printed electrodes [92] Copyright © 2017 Elsevier, (D) carbon black–carbon nanotubes [82], (E) magnetite nanoparticles/polydopamine [89] Copyright © 2017 Elsevier, (F) Palladium-cobalt nanoparticles/ carbon nanotubes [93] Copyright © 2017 Elsevier.
Figure 3. Schematic representation of different modification processes of working electrodes utilizing different nanomaterials (A) carbon black [82] Copyright © 2017 Elsevier, (B) molybdenum disulphide (MoS2) nanosheets [91] Copyright © 2017 Elsevier, (C) enzyme modified screen printed electrodes [92] Copyright © 2017 Elsevier, (D) carbon black–carbon nanotubes [82], (E) magnetite nanoparticles/polydopamine [89] Copyright © 2017 Elsevier, (F) Palladium-cobalt nanoparticles/ carbon nanotubes [93] Copyright © 2017 Elsevier.
Sensors 20 00103 g003
Table
Table 1. Different nomenclature given to metabolic syndrome (MetS) conditions over the years.
Table 1. Different nomenclature given to metabolic syndrome (MetS) conditions over the years.
YearNomenclatureRisk Factors IncludedProposed By
1923Hypertoni–Hyperglycemi–Hyperurikemi syndromeHypertension, hyperglycemia, hyperurecemiaKylin
1966Trisyndrome metaboliqueGout, diabetes, hyperlipidemiaCamus
1967Plurimetabolic syndromeHyperlipidemia, obesity, diabetes, hypertension, coronary heart diseaseAvogaro and Crepaldi
1968Wohlstands-syndrom (Syndrome of affluence)Hyperlipidemia, obesity, diabetes, hypertension, coronary heart diseaseMehnert and Kuhlmann
1981Metabolische-syndrom (Metabolic syndrome)Hyperlipidemia, hyperinsulinemia, obesity, diabetes, hypertension, gout, thrombophiliaHanefeld and Leonhardt
1988Syndrome XImpaired glucose tolerance, hyperinsulinemia, very low-density lipoprotein (VLDL), triglycerides, cholesterol, hypertension, low high-density lipoprotein (HDL)G.M. Reaven
1989Deadly quartetCentral adiposity, impaired glucose tolerance, hypertriglyceridemia, hypertensionKaplan
1991–1992Insulin resistance syndromeInsulin resistance, diabetes, hypertriglyceridemiaDeFronzo and Ferranini,
Haffner
1994Visceral fat syndromeVisceral fat, diabetes, dyslipidemiaNakamura and Matsuzawa
Table
Table 2. Various diagnostic criteria used for MetS.
Table 2. Various diagnostic criteria used for MetS.
AgencyRisk Factor
Body WeightInsulin ResistanceLipidsBlood PressureGlucoseOthers
World Health Organization (WHO), 1998Waist/hip >0.9 (men)
>0.85 (women)
or body mass index (BMI) >30 kg/m2		IGT/IFG/type 2 diabetes or lower insulin sensitivity
+ any 2 of the other factors 		TG ≥150 mg/dL and/or HDL <35 mg/dL (men)
<39 (women)		≥140/90 mm HgIGT/IFG/type 2 diabetesMicro-albuminuria
Urinary excretion rate >20 mg/min or albumin/creatinine >30 mg/g
European Group for the study of Insulin Resistance (EGIR), 1999Waist circumference
≥94 cm (men)
≥80 cm (men)		Plasma insulin
>75th percentile		TG ≥ 150 mg/dL and/or HDL <39 mg/dL≥140/90 mm HgIGT/fasting plasma glucose >110 mg/dLNone
National Cholesterol Education
Programme/Adult Treatment Panel III (NCEP/ATP III), 2001		Waist circumference ≥102 cm (men)
≥8 cm (men)		Any three of the five factors listedTG ≥150 mg/dL and/or HDL <40 mg/dL (men)
<50 (women)		≥130/85 mm Hg>110 mg/dLNone
American Association of Clinical Endocrinologists (AACE), 2003BMI ≥25 kg/m2IGT/IFG + any of the other factorsTG ≥ 150 mg/dL and/or HDL <35 mg/dL (men)
<39 (women)		≥130/85 mm HgFasting plasma glucose 110–126 mg/dL; post-prandial 140–200 mg/dLNone
International Diabetes Federation (IDF), 2005Ethnicity based values for waist circumference
>94 cm (Euro men)
>80 cm (Euro women)
>90 cm (Asian men)
>80 cm (Asian women)		Not listedTG ≥ 150 mg/dL and/or HDL <40 mg/dL (men)
<50 (women)		≥130/85 mm Hg>100 mg/dLNone
Impaired Glucose Tolerance (IGT); Impaired Fasting Glucose (IFG); Triglycerides (TG); High density lipoprotein (HDL).
Table
Table 3. Electrochemical sensors reported for sensing of dual and triple analytes reported.
Table 3. Electrochemical sensors reported for sensing of dual and triple analytes reported.
AnalyteNano-InterfaceEnzymes UsedTechniqueRef.
Dual AnalytesGlucose and H2O2Pt–Pd bimetallic clustersYesCV, Amp[30]
Glucose and CholesterolPoly-thionine filmNoCV, Amp[85]
Glucose and H2O2Au–Pd bimetallic nanoparticlesNoCV, Amp[91]
Glucose and Uric acidCarbon inkYesCA[92]
Glucose and H2O2Pd-CoCNTsNoCV, Amp, EIS[93]
Glucose and H2O2PdCu alloyNoCV, Amp[94]
Glucose and H2O2Co3O4NoCV, Amp[95]
Glucose and H2O2Cu2ONoCV, Amp, EIS[97]
Glucose and H2O2Silver–DNA hybrid nanoparticlesYesCV, Amp[98]
Glucose and H2O2CuO/rGO/Cu2ONoCV, Amp[99]
Glucose and MaltoseMWCNTsNoCV, Amp[100]
Glucose and UreaE-DNANoCV, Amp, EIS[101]
Glucose and H2O2PerovskiteNoAmp[102]
Glucose and H2O2CoSNoCV, Amp, EIS[103]
Glucose and H2O2Graphene wrapped CuO nanocubesNoCV, Amp[104]
Glucose and H2O2Ag nanowires-CSYesCV, Amp[105]
Triple AnalytesUric Acid, Dopamine, Ascorbic AcidCarbon black–carbon nanotube/polyimide compositeNoCV, DPV, Amp[81]
Ascorbic Acid, Dopamine and Uric AcidWater-soluble homogenous carbon black–chitosan inkNoCV, DPV, Amp[82]
Glucose, Uric Acid, CholesterolGold/titanium electrodeposited with polyaniline on platinum nanoparticlesYesAmp[87]
Ascorbic acid, Dopamine and Uric acidGold electrode patterned on polymethylmethacrylateNoCV, DPV[106]
Glucose, Ethanol and CholesterolPolydopamine-coated magnetic nanoparticlesYesCV, Amp[89]
Glucose, D-Fructose, Sucrose3-D Cu foamNoCV, A[107]
CV: cyclic voltammetry, A: amperometry, EIS: electrochemical impedance spectroscopy, DPV: differential pulse voltammetry, H2O2.hydrogen peroxide, Glu= glucose, Ag= silver, E-DNA= oligo nucleotide probe-based electrochemical DNA, Co3O4= cobalt oxide, Pt–Pd= platinum palladium bimetallic nanoparticles, MWCNT= multiwalled carbon nanotube, CuO=copper oxide, rGO= reduced graphene oxide, CoS= cobalt sulfide.

Share and Cite

MDPI and ACS Style

Sasya, M.; Devi, K.S.S.; Babu, J.K.; Balaguru Rayappan, J.B.; Krishnan, U.M. Metabolic Syndrome—An Emerging Constellation of Risk Factors: Electrochemical Detection Strategies. Sensors 2020, 20, 103. https://doi.org/10.3390/s20010103

AMA Style

Sasya M, Devi KSS, Babu JK, Balaguru Rayappan JB, Krishnan UM. Metabolic Syndrome—An Emerging Constellation of Risk Factors: Electrochemical Detection Strategies. Sensors. 2020; 20(1):103. https://doi.org/10.3390/s20010103

Chicago/Turabian Style

Sasya, Madhurantakam, K. S. Shalini Devi, Jayanth K. Babu, John Bosco Balaguru Rayappan, and Uma Maheswari Krishnan. 2020. "Metabolic Syndrome—An Emerging Constellation of Risk Factors: Electrochemical Detection Strategies" Sensors 20, no. 1: 103. https://doi.org/10.3390/s20010103

APA Style

Sasya, M., Devi, K. S. S., Babu, J. K., Balaguru Rayappan, J. B., & Krishnan, U. M. (2020). Metabolic Syndrome—An Emerging Constellation of Risk Factors: Electrochemical Detection Strategies. Sensors, 20(1), 103. https://doi.org/10.3390/s20010103

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop